P/B and P/S ratios remain key tools investors can use to find stocks trading below intrinsic value.
Key sectors include biotech, medical technology, e-commerce, and banking, all with discounts up to 50%.
Undervalued stocks with long-term growth potential include NewAmsterdam Pharma Stock, Alphatec Holdings Shares, and more.
Value hunters are increasingly zeroing in on stocks that may be trading well below their intrinsic worth as US markets continue to swing between brief rallies and sudden pullbacks. S&P 500 and Nasdaq have moved slightly lower after an early-week bounce and uncertainty easing around the potential end of the government shutdown.
Investors are now turning their attention to companies whose prices do not reflect their long-term fundamentals. November 2025 is proving to be a fertile month for identifying undervalued opportunities in banking, biotech, medical technology, and e-commerce.
A recent valuation screen highlights many US stocks that seem quite underpriced relative to their estimated fair value. Old National Bancorp, Nicolet Bankshares, Huntington Bancshares, Genius Sports, Fifth Third Bancorp, Byrna Technologies, and even pharmaceutical giant AbbVie trade at a discount close to 50% compared to their calculated fair values. Below are some of the biggest value investing opportunities at a glance:
Fair Value: The stock has a Near 49% Upside for Old National Bancorp.
Huntington Bancshares (HBAN): These shares are priced at an inexpensive 49.1% discount.
Genius Sports (GENI): It is one of the top undervalued stocks in November 2025 with an undervaluation of about 49.6%
AbbVie (ABBV): The stock is estimated to be trading at a 49.7% discount, the largest in this group.
Although the above names show a remarkable valuation gap, three companies-NewAmsterdam Pharma, Alphatec Holdings, and Pattern Group-stand out. Scroll down to find out more about these top US stock picks for November 2025!
Also Read: Groww Stock on Fire: Will Q2 Results Support the Hype?
NewAmsterdam Pharma, a late-stage player in metabolic disease treatments, stands out as this month's undervalued pick. Trading around $38.97, its stock is well below the estimated fair value of $69.01, so it is an undervalued investment by 43.5%. Even though analysts forecast revenue to increase by over 61% year over year, the gains are much higher than the general market. The company posted a $72 million net loss in a tough quarter.
While the company's roadmap to potential profitability in three years is encouraging, recent insider selling has warranted attention. Its strong R&D pipeline and anticipated revenue surge make it one of the best undervalued stocks to watch in November 2025.
Alphatec Holdings develops advanced surgical technologies for spinal care and continues to show promising growth signals. The stock was trading at $20.24 against an intrinsic value of $24.89. Alphatec appeared undervalued by 18.7% at the time of writing.
The company posted a third-quarter loss of $28.5 million, but raised its fiscal guidance afterward. It reflects management confidence in its expanding product pipeline. Revenue is expected to grow 14.1% annually, higher than the broader healthcare sector. Though insider selling has cropped up recently, the company’s longer-term direction is favorable, backed by high demand for its solutions in treating disorders of the spine.
Pattern Group runs a rapidly scaling ecommerce optimization platform powered by AI and advanced analytics. The company currently trades at a 29.8% discount, with its shares trading at $17.70 versus a fair value near $25.21. Although it reported a quarterly loss of $59 million, Pattern is among the few recently listed companies with consistent revenue momentum. The company generated more than $639 million last year.
This further reinforces the strong growth outlook, as the company expects fourth-quarter revenue between $680 million and $700 million. The stock has been very volatile since its IPO. However, Pattern's dominant position in data-driven ecommerce acceleration makes it a top undervalued contender.
While investors conventionally use the P/E ratio, those analyzing undervalued or loss-making firms need to consider other metrics, such as the price-to-sales or price-to-book ratios. In industries characteristically laden with tangible assets-banking and manufacturing, the P/B ratio serves as an efficient instrument for underpriced stock identification that could yield returns.
A P/B ratio below 1 generally indicates undervaluation, but it must be evaluated in conjunction with other ratios such as P/E, PEG, debt levels, and industry averages.
Many companies screening strongly on low P/B include:
StoneCo (STNE)
Great Lakes Dredge & Dock (GLDD)
EnerSys (ENS)
MillerKnoll (MLKN)
Keros Therapeutics (KROS)
These companies carry not only attractive valuations but also boast strong projected earnings growth and high Zacks Ranks (1 or 2). Hence, strengthening their investment cases even further.
Also Read: US Stock Market Today: NASDAQ Slides 1.9% & S&P 500 Dips 1.4% as Tech Giants Struggle with AI Valuation and Economic Woes
The stock market is volatile. Growth stocks are cooling off after a long rally, and undervalued stocks are regaining investor interest. Whether you're drawn to high-potential biotech names like NewAmsterdam, fast-growing ecommerce players like Pattern Group, or financially strong industrial names with low price-to-book ratios, the above list has many options for you to choose from. November presents compelling entry points for long-term investors seeking value.
1. What does it mean when a stock is undervalued?
An undervalued stock is trading at below its estimated intrinsic value. Investors perceive opportunities for price growth when the market corrects this disparity, along with long-term return opportunities.
2. Why are P/B and P/S ratios so significant in value investing?
These help indicate if a stock is trading below its actual worth, using price-to-book and price-to-sales ratios. They are especially useful for companies in their loss-making or asset-heavy stages to give investors a better representation of the company's valuation.
3. What stocks are considered top undervalued picks in November 2025?
Top undervalued stocks include NewAmsterdam Pharma, Alphatec Holdings, and Pattern Group. For this article, the author has selected stocks with solid projected revenue growth and/or significant price discounts to estimated fair value.
4. How does insider selling impact the potential of an undervalued stock?
Insider selling can signal caution or reduced confidence from management. While that does not necessarily mean a company will underperform, investors should consider it in conjunction with evaluating risk and fundamentals and growth potential.
5. Are undervalued stocks a safe investment in volatile markets?
Undervalued stocks offer potential gains but still carry risk, especially in volatile markets. Much of this can be offset through diversification and a careful assessment of growth prospects, balance sheets, and valuation metrics.